Oral administration of a 2-aminopyrimidine robenidine analogue (NCL195) significantly reduces infection and reduces infection in combination with sub-inhibitory colistin concentrations in a bioluminescent mouse model.

We have previously reported promising activity of the first-generation 2-aminopyramidine robenidine analogue NCL195 against Gram-positive bacteria (GPB) when administered via the systemic route. In this study, we examined the efficacy of oral treatment with NCL195 (± low-dose colistin) in comparison to oral moxifloxacin in bioluminescent and peritonitis-sepsis models. Four oral doses of 50 mg/kg NCL195, commencing immediately post-infection, were administered at 4 h intervals in the peritonitis-sepsis model.